Posted 26 May 2016

Dr. Antonella Chadha Santuccione

Streamlining and harmonising the global drug development pathway for Alzheimer's disease treatment



Dr. Antonella Chadha Santuccione from the Swiss Agency for Therapeutic Products gives a regulator’s view on how (besides a fast-track line), an early dialogue with Authorities, combined with adequate, and agreed upon preclinical work and measures to ensure the safety and interest of the patient, is the best way forward to cut the drug development time and save costs.

About speaker:
Dr. Antonella Santuccione Chadha joined the Swiss Agency for Therapeutic Products in Bern in 2014 as a Specialised Clinical Reviewer in the field of psychiatric disorders. Previous to this, she was appointed by Roche as Medical Manager for Psychiatry. Before joining the industry, she worked as a neuroscientist and a medical doctor at the Psychiatry University Hospital in Zurich.
During this period she extensively investigated the pathogenesis of Alzheimer’s disease (AD) and other neurodegenerative disorders. The focus of her studies was to identify a possible immunotherapy for AD.